Literature DB >> 14726044

Effect of moderate pressure distention on the human saphenous vein vasomotor function.

Elena B Okon1, Michael J Millar, Christine M Crowley, Jamil G Bashir, Richard C Cook, York N Hsiang, Bruce McManus, Cornelis van Breemen.   

Abstract

BACKGROUND: Manual pressure distension, which is commonly applied to the human saphenous vein graft for coronary artery bypass, is believed to have detrimental consequences for the graft patency. The vasomotor function of the vein after distention during surgical preparation for grafting and after distention in laboratory conditions at pressure of 50 to 600 mm Hg was studied. The effect of a combination of vasodilative agents to prevent vasospasm was also tested.
METHODS: The contractile and dilatory responses of distended and undistended human saphenous veins and those after drug treatment were examined in organ baths under isometric conditions.
RESULTS: Distention at the pressure range 100 to 300 mm Hg resulted in an increased contractile response of the saphenous vein to both alpha-adrenergic activation with 50 micromol/L phenylephrine (153.73% +/- 15.69%) and depolarization with 80 mmol/L K(+) (141.03% +/- 15.13%) in comparison with the undistended vein and did not impair the relaxation. In contrast manual distention during surgical preparation abolished the contractile response and impaired the relaxation. The application of a combination of vasodilative drugs (alpha-adrenergic antagonist phenoxybenzamine, 10 micromol/L, Rho-kinase inhibitor HA-1077, 50 micromol/L, and calcium blocker nicardipine, 1 micromol/L) eliminated the contractile response of the vein to phenylephrine and 80 mmol/L K(+). This effect was sustained more than 20 hours after the washout of the drugs.
CONCLUSIONS: The distention of the human saphenous vein at moderate pressure combined with the application of the effective combination of vasodilative drugs before grafting into the arterial circulation could be a beneficial alternative to the current practice of uncontrolled pressure distension.

Entities:  

Mesh:

Year:  2004        PMID: 14726044     DOI: 10.1016/j.athoracsur.2003.06.007

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Pressure control during preparation of saphenous veins.

Authors:  Fan Dong Li; Susan Eagle; Colleen Brophy; Kyle M Hocking; Michael Osgood; Padmini Komalavilas; Joyce Cheung-Flynn
Journal:  JAMA Surg       Date:  2014-07       Impact factor: 14.766

2.  Detrimental effects of mechanical stretch on smooth muscle function in saphenous veins.

Authors:  Kyle M Hocking; Colleen Brophy; Syed Z Rizvi; Padmini Komalavilas; Susan Eagle; Marzia Leacche; Jorge M Balaguer; Joyce Cheung-Flynn
Journal:  J Vasc Surg       Date:  2010-12-13       Impact factor: 4.268

3.  Arterialization of a vein graft promotes cell cycle progression through Akt and p38 mitogen-activated protein kinase pathways: impact of the preparation procedure.

Authors:  Ada W Y Chung; Jerry Wong; Honglin Luo; York N Hsiang; Cornelis van Breemen; Elena B Okon
Journal:  Can J Cardiol       Date:  2007-12       Impact factor: 5.223

Review 4.  Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia.

Authors:  Michael J Osgood; Charles R Flynn; Padmini Komalavilas; Colleen Brophy
Journal:  Vascular       Date:  2012-10-26       Impact factor: 1.285

5.  Traditional graft preparation decreases physiologic responses, diminishes viscoelasticity, and reduces cellular viability of the conduit: A porcine saphenous vein model.

Authors:  Eric S Wise; Kyle M Hocking; Weifeng Luo; Daniel L Feldman; Jun Song; Padmini Komalavilas; Joyce Cheung-Flynn; Colleen M Brophy
Journal:  Vasc Med       Date:  2016-05-23       Impact factor: 3.239

6.  The Case for Endothelial Preservation via Pressure-Regulated Distension in the Preparation of Autologous Saphenous Vein Conduits in Cardiac and Peripheral Bypass Operations.

Authors:  Eric S Wise; Colleen M Brophy
Journal:  Front Surg       Date:  2016-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.